07.08.2015 • News • Boehringer Ingelheim • Dede Willams • generics

Boehringer Selling US Generics Arm to Hikima

Boehringer Ingelheim, the German drugmaker, has sold its US generics business for $2.7 billion to London-based Jordanian-British owned Hikima Pharmaceuticals. At the same time, it has taken a 6.7% stake in the company.

The acquisition price for Roxane is $1.2 billion, but Boehringer is also picking up $40 million in Hikima shares along with milestone payments of up to $125 million.

Nucleus of the German company’s generics arm is Roxane, based in the US state of Ohio. The firm produces and markets generic versions of Boehringer’s products, along with some of its

In 2014, Hikima bought Boehringer subsidiary Bedford Laboratories, which manufactures injectables.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.